Raising capital for your business idea is likely to be one of the hardest and most nerve-wracking things you do as a researcher or entrepreneur. We often read reports in the media about companies gaining large funding rounds or VCs raising large funds, but as a scientist or medic: how can I engage with the investment community? And whilst most of us will have seen the popular Dragon’s Den television programme: how much does this differ to the reality?
At this event we will learn the basics of how to approach different types of investors, what to ask for, what to give away (and not), how the process works and useful tips from the investors themselves! We have top representatives from UK crowd funding platforms, university-linked funds, local Oxford-based investors, entrepreneurs and an international VC: all waiting to answer your questions!
Join the Oxford Innovation Forum on Wednesday 15th March for an evening of presentations centred around these themes. See below for the detailed programme.
This session is part of a series on entrepreneurship in health and life-sciences organised by Innovation Forum Oxford, in collaboration with the MRC Weatherall Institute of Molecular Medicine.
This lecture series is a part of the IMAGINE IF! accelerator programme, designed to inspire and foster grassroots innovation. The business idea competition provides support, mentorship and opportunity to secure $30,000 of non-diluted capital.
Note: If you are already registered for the complete lecture series there is no need to register again for this event. Please send any booking queries to [email protected].
Welcome from Innovation Forum Oxford
What do you need to know about funding for startups
Andy McLean (Oxford Sciences Innovation)
Panel discussion: How to raise capital: From who and from where?
Chair: Andy McLean (OSI)
Andrea Mica (Oxford Technology)
Tom Britton (Syndicate Room)
Dr Michael Stein (CEO of Oxstem)
Maina Bhaman (Touchstone Innovations)
Andrew McLean is the lead life sciences investor for Oxford Sciences Innovation. OSI is a £350 million company investing in the most exciting start-ups built on world-leading Oxford science. Prior to joining OSI Andrew consulted in the pharmaceutical & biotech practice at McKinsey. Andrew is a physician by training, studied philosophy, politics & economics at Christ Church in Oxford and his work background includes stints in wine shops, hospitals & Goldman Sachs.
Dr. Michael Stein is a serial entrepreneur, medical scientist, business executive and strategic advisor with senior experience in healthcare, drug discovery, therapeutics, media and software industries. Dr. Stein is passionate about healthcare and the environment and trained in financial risk management. A dynamic team builder with natural instincts for leadership and communication, he is highly skilled in business development at the highest levels of government and corporate enterprise. Has inspired and built several successful internet and healthcare businesses, and able to support development, growth and strategic advice for early stage companies or spinouts from Universities or larger corporations.
Dr. Michael Stein is the current Chairman and CEO of both OxStem Ltd. and Province Tx (Oy). Oxstem is a drug discovery company targeting stem and progenitor cells which was recently spun out of the University of Oxford. Michael will continue as CEO at OxStem having raised a £16.9m series A (a UK record for a university spin-out), until he has found his successor (in process). ProVince Tx, a spin-out company from the University of Helsinki, is a developer of novel vaccination-based cancer therapies. Its unique approach to immunotherapy in cancer combines an oncolytic virus with tumour specific peptides, for a rapidly adaptable and long lasting cancer vaccination. In 2001, he co-founded the Map of Medicine Ltd (the Map) with University College London. The Map was nationally licensed across NHS England in 2005 and is primarily used by commissioners for planning healthcare services across the continuum of care. The Map was acquired by Hearst Business Media (HBM) in 2008, and Michael transitioned as executive vice-president (healthcare innovation) to HBM until 2011. Since 2011, Michael has assisted a number of start-up businesses, notably serving as the founding CEO and executive chairman for Doctor Care Anywhere, acquired by Synergix in 2015. Michael graduated as a medical doctor (Honours) and biochemist (First Class Honours) from the University of Cape Town (1988) and from the University of Oxford (Rhodes Scholar) with a doctorate in physiological sciences (Immunology). He subsequently was appointed as a Junior Research Fellow in Medicine at Trinity College, Oxford (1992-95).
Born in Los Angeles, Tom moved to the UK to play football and after three fairly successful years realised it was time to focus on his non-sporting career. Before joining SyndicateRoom as a co-founder Tom worked in product development on a number of software-based projects including managing the development of the mobile applications for TheTrainline.
Tom completed his MBA at Cambridge where he focused on developing start-ups and has taken a keen interest in ventures focused on helping other start-ups. Tom leads SyndicateRoom's website development team though his skills and experience ensure that he does a lot more than just that. In his spare time Tom volunteers for Camp Footprints, rock climbs, and still plays the odd five aside game.
Maina has led a number of investments in Innovations’ healthcare portfolio including recent investments into Psioxus Therapeutics and Cellmedica . Maina currently serves on the board of Autifony Therapeutics, Cell Medica, Ixico ,Psioxus Therapeutics and Topivert Pharma. Maina was also served on the board of Acrobot and Molecular Vision Ltd. Maina joined Innovations in 2006 and prior to that worked in the research and development team at Celltech (previously Oxford Glyco Sciences). Maina’s experience includes Chimeric Therapies, a cell therapy start-up based in Philadelphia and GeneMedicine, a gene therapy company based in Houston, Tx. Maina has a BSc from the University of Texas at Austin and an MBA from the Imperial Business School.
Wednesday, March 15th 2017
18:00 – 20:00 (GMT)
Lecture Theatre 1